Literature DB >> 3802072

Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells.

R A Hromas, P A Andrews, M P Murphy, C P Burns.   

Abstract

Little is understood about the mechanism of acquired resistance to the widely used antineoplastic drug, cisplatin. The cisplatin-resistant murine leukemia L1210 cell line L1210/PAM has an elevated cellular glutathione content, as compared to its sensitive parent cell line, L1210/*. Exposure to D,L-buthionine-S,R-sulfoximine reduced L1210/PAM cells' glutathione content to nearly that of L1210/* cells and abrogated the resistance to cisplatin.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3802072     DOI： 10.1016/0304-3835(87)90067-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  16 in total

1.  Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum.

Authors:  K Ikeda; K Miura; S Himeno; N Imura; A Naganuma
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.

Authors:  G Chen; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 3.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Cisplatin inhibition of anthrax lethal toxin.

Authors:  Mahtab Moayeri; Jason F Wiggins; Robin E Lindeman; Stephen H Leppla
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 5.  Causes and problems of nonresponse or poor response to drugs.

Authors:  P Salvà Lacombe; J A García Vicente; J Costa Pagès; P Lucio Morselli
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

6.  Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.

Authors:  R D Christen; D K Hom; D C Porter; P A Andrews; C L MacLeod; L Hafstrom; S B Howell
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

7.  cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.

Authors:  M G Ormerod; C O'Neill; D Robertson; L R Kelland; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

8.  Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.

Authors:  S Y Sharp; P Mistry; M R Valenti; A P Bryant; L R Kelland
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells.

Authors:  G Chen; K J Hutter; W J Zeller
Journal:  Cell Biol Toxicol       Date:  1995-10       Impact factor: 6.691

10.  Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.

Authors:  H P Hofs; D J Wagener; V de Valk-Bakker; H van Rennes; A J van Zeist; L A van den Broek; H C Ottenheijm
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.